Roche’s presence in neuroscience is overshadowed by the company’s large cancer portfolio and pipeline. The Swiss pharmaceutical giant is positioning itself to expand in both therapeutic areas through ...

The molecular glue degrader medicines furthest along in development are potential cancer treatments, but Monte Rosa Therapeutics is also researching how this therapeutic modality can treat ...

Shares of Monte Rosa TherapeuticsGLUE surged to a nearly four-year high Tuesday after the biotech company said all four patients in a prostate cancer study responded to its experimental treatment.

Monte Rosa Therapeutics’ plan to develop a molecular glue degrader in a wide range of cancers has come unstuck. Biomarker-positive patients were rarer than expected in some tumor types, prompting the ...

Don’t stop Monte Rosa Therapeutics now. The Boston-based biotech is having a ball after signing a deal with Novartis to the tune of $150 million for a molecular glue degrader, developed using the ...

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, has made significant advancements in drug discovery as highlighted in a cover article published in Science. The research ...

Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some of ...

Monte Rosa Therapeutics (GLUE) announced a public offering of 11,125,000 shares of its common stock at $24.00 each. It will also offer pre-funded warrants to purchase 1,375,000 shares at a price of ...

Shares of Monte Rosa Therapeutics, Inc. (GLUE) surged after the company reported positive interim phase 1 results of MRT-8102, its wholly owned NEK7 molecular glue degrader. We saw significant ...

BOSTON, Mass., Sept. 15, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, ...

Monte Rosa Therapeutics Inc. (NASDAQ:GLUE) stock is surging on Monday, with a session volume of 11.67 million compared to the average volume of 408.08 thousand as per data from Benzinga Pro. Monte ...